NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 |
|
|
| Completed | 1 | 14 | US | Natural Killer (NK) Cells, ALT803, Cytokine | Brenda Cooper, MD | Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloproliferative Syndromes, Plasma Cell Myeloma, Colon Carcinoma, Adenocarcinoma of Rectum, Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcoma | 06/21 | 02/23 | | |
